| dc.contributor.author | Monanabela, Khathatso B. | |
| dc.contributor.author | van Huyssteen, Mea | |
| dc.contributor.author | Coetzee, Renier | |
| dc.date.accessioned | 2023-03-08T08:58:22Z | |
| dc.date.available | 2023-03-08T08:58:22Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Monanabela, K. B. et al. (2019). Describing medicine therapy management of type 2 diabetes mellitus at primary health care facilities in Cape Town. Journal of Interdisciplinary Health Science, 24, a1051. https://doi.org/10.4102/hsag.v24i0.1051 | en_US |
| dc.identifier.issn | 2071-9736 | |
| dc.identifier.uri | https://doi.org/10.4102/hsag.v24i0.1051 | |
| dc.identifier.uri | http://hdl.handle.net/10566/8552 | |
| dc.description.abstract | Rational medicine use aims to optimise chronic disease management and prevent
episodes of hospitalisation that economically burden the health care system. Diabetes mellitus
is one of the most prevalent chronic diseases globally, yet more than 60% of patients with
diabetes are not optimally managed according to their therapeutic glycaemic targets. To describe the use of glycated haemoglobin (HbA1c) and fasting plasma glucose results
in guiding treatment changes in patients with type 2 diabetes mellitus. Public sector primary health care facilities in the Cape Town Metropolitan Region in
South Africa. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | AOSIS | en_US |
| dc.subject | Glycated haemoglobin | en_US |
| dc.subject | Type 2 diabetes mellitus | en_US |
| dc.subject | World Health Organization (WHO) | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | South Africa | en_US |
| dc.title | Describing medicine therapy management of type 2 diabetes mellitus at primary health care facilities in Cape Town | en_US |
| dc.type | Article | en_US |
